Synarel

(Nafarelin)

Small molecule

Pfizer

Synarel is one of 38 small molecule programs targeting Endometriosis. It is currently in development.

Indications

Total Trials

Active Trials

Competitors

FDA Application

NDA/BLA/ANDA regulatory filings

Pipeline

Status by Indication[3][1]

Indication

EndometriosisActive, not recruiting

EndometriosisPhase 1/Phase 2

Active, not recruiting

Competition

Competitive Landscape

199 competitors in Endometriosis

#DrugCompanyPhaseTrials

Orilissa

AbbVie

Phase 3

16 2

Revia

Teva

Phase 3

1 3

Lupron

EEastern Cooperative Oncology Group

Phase 3

1 4

Firmagon

Ferring

Phase 3

1 5

Trental

VValidus Pharmaceuticals

Phase 3

1 6

Esketamine Hydrochloride

TThe Second Hospital of Anhui Medical University

Phase 3

1 7

Add-Back

KKissei Pharmaceutical Co., Ltd.

Phase 3

4 8

Visanne

Bayer

Phase 3

2 9

Triptorelin Acetate PR 1-Month

Ipsen

Phase 3

1 10

NPC-01

NNobelpharma

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2027

Phase 1Not yet recruiting

Pregnancy

NCT06870266

Clinical

Trials by Indication[1]

Pregnancy1 trial

Comparison of Pregnancy Rates in Modified Natural Frozen Embryo Transfer (FET) Cycle After Luteal Support with GnRH Agonist Versus Progesterone

Not yet recruiting·SShaare Zedek Medical Center·Phase 1·NCT06870266·150 enrolled

IVF1 trial

Injection Free IVF

Withdrawn·IInsel Gruppe AG, University Hospital Bern·Phase 2·NCT04850261

Endometriosis1 trial

Endometriosis : Traditional Medicine vs Hormone Therapy

Completed·NNational Center for Complementary and Integrative Health (NCCIH)·Phase 1/2·NCT00034047·50 enrolled

Regulatory

FDA Approval Timeline[4]

Feb 13, 1990

SYNAREL

NDA NDA019886

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for Nafarelin. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Nafarelin compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Nafarelin. EMBL-EBI & Wellcome Sanger Institute.
[4]
OpenFDA — FDA approval records (NDA NDA019886). U.S. Food & Drug Administration.
[5]
SEC EDGAR — Pfizer company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Company: Pfizer

Synarel

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2027

Trials by Indication[1]

Pregnancy1 trial

IVF1 trial

Endometriosis1 trial

FDA Approval Timeline[4]

References

Drug Info

Quick Facts

Related News